The Liver Disease Nobody Talks About Just Got a New Weapon

Brelovitug takes a different approach entirely. It's a monoclonal antibody that targets HBsAg, the surface protein that coats both hepatitis B and hepatitis delta particles. By binding to that protein, the antibody neutralizes circulating virus and helps clear out the massive cloud of viral debris floating in the bloodstream. If bulevirtide changes the locks, brelovitug is more like hiring a bounty hunter to round up every intruder already roaming the neighborhood.

There's a clever bonus to this strategy. HDV patients carry an enormous burden of HBsAg in their blood, and that antigen load essentially exhausts the immune system. By clearing it out, brelovitug may help restore the body's own antiviral defenses, a two-for-one that could matter over the long haul.

The Phase 2b Preview Was Already Impressive

Investors had reason to be optimistic going into this readout. Mirum's earlier Phase 2b data from the same AZURE-1 trial showed remarkable numbers. In the 300 mg weekly dosing arm, every single patient (100%) achieved a virologic response. ALT normalization hit 45%, and 45% of patients met the full composite endpoint.

The less frequent dosing arm (900 mg once monthly) posted 75% virologic response and 35% on the composite. Meanwhile, patients in the delayed-treatment group scored a flat zero on the composite. That kind of separation between drug and control is the stuff regulatory reviewers love to see.

Wall Street Was Already Leaning In

The market had positioned itself for good news. Mirum shares closed at $73.57 on September 25 and ticked up about 3% in overnight trading ahead of the announcement. Analysts had flagged this readout as the company's biggest near-term catalyst, with at least one firm carrying a $100 price target.

The logic is straightforward. If brelovitug gets approved, Mirum goes from being a small hepatology company to owning a potential blockbuster in a space with almost no competition. A successful BLA submission in 2027 would put commercial launch within sight, and the HDV market is wide open.

A Crowded Pipeline Is Forming (Finally)

Brelovitug isn't the only challenger coming for bulevirtide's throne. Vir Biotechnology is running its own Phase 3 program with a combination of tobevibart and elebsiran, using a dual-mechanism approach that pairs an antibody with RNA interference technology. Vir has even designed a head-to-head study (ECLIPSE 3) directly against bulevirtide, a clear signal that the company is thinking about payer negotiations, not just clinical wins.

Then there's lonafarnib (Jitixib) from EIT Pharma, an oral prenylation inhibitor that could appeal to patients who want a pill instead of an injection. It's reportedly under FDA review. And further back in the pipeline, Johnson & Johnson has an HBV-targeted siRNA (JNJ-73763989) being developed in combination strategies that aim for something closer to a functional cure.

The competitive landscape is shifting from "anything is better than nothing" to genuine differentiation. That's great news for patients and a headache for Gilead, which now has to defend bulevirtide against multiple late-stage challengers with distinct mechanisms.

Why This Matters Beyond the Stock Price

HDV has been one of medicine's most neglected diseases for decades. It causes the most severe form of viral hepatitis, accelerating cirrhosis and liver cancer faster than hepatitis B or C alone. Yet in many parts of the world, patients aren't even tested for it. The disease disproportionately affects regions with limited healthcare infrastructure, which means millions of people have been suffering in silence.

A second approved therapy wouldn't just give doctors another option. It would validate HDV as a real market, attract more investment, and incentivize the kind of screening programs that could identify patients before their livers give out.

Mirum still needs to release the full Phase 3 dataset, navigate FDA discussions, and execute on a commercial strategy. None of that is guaranteed. But for a disease that went decades without a single approved drug, having a second one knocking on the door feels like progress worth celebrating.

The Cancer Therapy That's Curing Lupus

Adicet Bio's off-the-shelf CAR-T therapy, originally built for cancer, just produced durable lupus remissions in a Phase 1 trial. The results could validate the "immune reset" approach and upend decades of chronic immunosuppression.